Cyxone AB logo

CYX TO3 - Cyxone AB Share Price

SEK0.02 0.0  0.0%

Last Trade - 16/09/19

Micro Cap
Market Cap £23.3m
Enterprise Value £19.8m
Revenue £n/a
Position in Universe th / 1783
Unlock CYX TO3 Revenue
Relative Strength (%)
1m -98.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.021 0.000 0.000 0.000 0.030 0.030 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Cyxone AB revenues was not reported. Net loss increased 82% to SEK24.4M. Higher net loss reflects Other External Expenses -Third Parties increase from SEK10.6M to SEK21.4M (expense), Financial costs increase from SEK0K to SEK88K (expense), Other Operating Income decrease from SEK48K (income) to SEK0K. Basic Earnings per Share excluding Extraordinary Items decreased from -SEK0.36 to -SEK0.50.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CYX TO3 Revenue Unlock CYX TO3 Revenue

Net Income

CYX TO3 Net Income Unlock CYX TO3 Revenue

Normalised EPS

CYX TO3 Normalised EPS Unlock CYX TO3 Revenue

PE Ratio Range

CYX TO3 PE Ratio Range Unlock CYX TO3 Revenue

Dividend Yield Range

CYX TO3 Dividend Yield Range Unlock CYX TO3 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYX TO3 EPS Forecasts Unlock CYX TO3 Revenue
Profile Summary

Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Shares in Issue 49,080,380
Free Float (0.0%)
Eligible for
CYX TO3 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CYX TO3
Upcoming Events for CYX TO3
Frequently Asked Questions for Cyxone AB
What is the Cyxone AB share price?

As of 16/09/19, shares in Cyxone AB are trading at SEK0.02, giving the company a market capitalisation of £23.3m. This share price information is delayed by 15 minutes.

How has the Cyxone AB share price performed this year?

Shares in Cyxone AB are currently trading at SEK0.02 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cyxone AB price has moved by % over the past year.

What are the analyst and broker recommendations for Cyxone AB?

There are no analysts currently covering Cyxone AB.

When will Cyxone AB next release its financial results?

Cyxone AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cyxone AB dividend yield?

Cyxone AB does not currently pay a dividend.

Does Cyxone AB pay a dividend?

Cyxone AB does not currently pay a dividend.

When does Cyxone AB next pay dividends?

Cyxone AB does not currently pay a dividend.

How do I buy Cyxone AB shares?

To buy shares in Cyxone AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cyxone AB?

Shares in Cyxone AB are currently trading at SEK0.02, giving the company a market capitalisation of £23.3m.

Where are Cyxone AB shares listed? Where are Cyxone AB shares listed?

Here are the trading details for Cyxone AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: CYX TO3
What kind of share is Cyxone AB?

We were not able to load our ranking data for Cyxone AB

Is there a Cyxone AB share price forecast 2020?

We were not able to load any forecast data for Cyxone AB.

How can I tell whether the Cyxone AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyxone AB. Over the past six months, the relative strength of its shares against the market has been -95.62%. At the current price of SEK0.02, shares in Cyxone AB are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cyxone AB PE Ratio?

We were not able to find PE ratio data for Cyxone AB.

Who are the key directors of Cyxone AB?

Cyxone AB's management team is headed by:

Bert Junno - CHM
Theresa Comiskey Olsen - DRC
Saad Gilani - DRC
Mikael Lindstam - COO
Ola Skanung - CEO
Malin Berthold - OTH
Who are the major shareholders of Cyxone AB?

Here are the top five shareholders of Cyxone AB based on the size of their shareholding:

Similar to CYX TO3
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.